Medical Cannabis use for pediatric oncology patients: single institution experience.

Ofir et al. ·Pediatric Hematology and Oncology

Gemischt GRADE Sehr niedrig 25 Zitate

Stichproben = 50 Pat.

Dauer2010–2017

EndpunktPatientenberichtete…

Verblindungn.a.

DesignRetrospektive Fallserie

Cannabinoidvollspektrum

Kernaussage

In 80% der Fälle wurden positive Effekte berichtet, jedoch mit vereinzelten Nebenwirkungen, insbesondere bei Rauchern.

Zusammenfassung

Retrospektive Fallserie (n=50 Kinder/Jugendliche mit Krebs, 2010–2017) zu medizinischem Cannabis als Supportivtherapie; Hauptindikation Übelkeit/Erbrechen; positive Wirkung in 80% der Fälle (Eltern-/Patientenangabe); gut verträglich, selten Toxizität (häufigste UAW: Halsbrennen, Angstattacken bei Rauchern).

PopulationKinder, Jugendliche und junge Erwachsene mit verschiedenen Krebserkrankungen, n=50, pädiatrische Onkologie (2010–2017)

InterventionMedizinisches Cannabis (Öltropfen 60%, Rauchen 22%, Vaporisierung, Kapseln oder Kombinationen) zur Symptomkontrolle unter Antikrebstherapie

OutcomePositive Effekte in 80% der Fälle berichtet (von Patienten/Eltern); häufigste Nebenwirkungen: Halsreizung und Angstattacken beim Rauchen

Vertrauen in die Evidenz

Sehr niedrig

Niedrigste GRADE-Stufe, die Effektschätzung bleibt unsicher.

Herabgestuft wegen

Ungenauigkeit

Qualitätsprofil

Größe ★★★★★

Verblindung —

Effektstärke Gemischt

Zitate / Jahr ★★★★★

Autoren

Ofir R, Bar-Sela G, Weyl Ben-Arush M, Postovsky S.

DOI 10.1080/08880018.2019.1630537↗

Design: Retrospektive Fallserie

Abstract

Medical Cannabis (MM) is widespread in many medical fields, including oncology, with limited use in pediatric oncology where research is scarce and often shows conflicting results. This research focuses on alleviating side effects of anticancer treatment as an integral part of supportive and palliative care of children with cancer. We report our experience with MM treatment in 50 children, adolescents, and young adults with different types of cancer during 2010-2017. The main indications for prescriptions were nausea and vomiting, decreased mood, disturbed sleep, and pain. The medication was supplied to 30 patients via oil drops (60%) and 11 via smoking (22%), followed by vaporization, capsules, or combinations of various routes. Positive effects were reported by verbal children and parents in 80% of cases. MM was generally well tolerated with few patients reporting toxicity, with the most common adverse reactions being burning in the throat and anxiety attacks in subjects who chose to smoke the product. We conclude that MM may serve as a potentially useful complementary therapy to conventional supportive treatment of children suffering from cancer at the end of life. Further research is needed on the safety and efficacy and the consequences of prolonged use in pediatric populations.

„Was dem Handeln im Weg steht, wird zum Weg.“ — Marc Aurel